Does the media prefer IXHL or LENZ?

In the previous week, LENZ Therapeutics had 2 more articles in the media than Incannex Healthcare. MarketBeat recorded 4 mentions for LENZ Therapeutics and 2 mentions for Incannex Healthcare. LENZ Therapeutics' average media sentiment score of 1.04 beat Incannex Healthcare's score of 0.63 indicating that LENZ Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incannex Healthcare 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LENZ Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer IXHL or NRXP?

In the previous week, NRx Pharmaceuticals had 6 more articles in the media than Incannex Healthcare. MarketBeat recorded 8 mentions for NRx Pharmaceuticals and 2 mentions for Incannex Healthcare. Incannex Healthcare's average media sentiment score of 0.63 beat NRx Pharmaceuticals' score of 0.61 indicating that Incannex Healthcare is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incannex Healthcare 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NRx Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is UNCY or IXHL more profitable?

Incannex Healthcare's return on equity of -81.01% beat Unicycive Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Unicycive Therapeutics N/A -91.50% -61.47% Incannex Healthcare N/A -81.01% -76.11%

Does the media prefer UNCY or IXHL?

In the previous week, Unicycive Therapeutics had 26 more articles in the media than Incannex Healthcare. MarketBeat recorded 28 mentions for Unicycive Therapeutics and 2 mentions for Incannex Healthcare. Incannex Healthcare's average media sentiment score of 0.63 beat Unicycive Therapeutics' score of -0.01 indicating that Incannex Healthcare is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Unicycive Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 20 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral Incannex Healthcare 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is MIST or IXHL more profitable?

Incannex Healthcare's return on equity of -81.01% beat Milestone Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Milestone Pharmaceuticals N/A -288.33% -58.27% Incannex Healthcare N/A -81.01% -76.11%

Incannex Healthcare (IXHL) Competitors

$3.26 +0.01 (+0.31%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$3.26 0.00 (0.00%)

As of 09/11/2026 07:30 PM Eastern

Compare

IXHL vs. LFCR, LENZ, NRXP, UNCY, and MIST

Should you buy Incannex Healthcare stock or one of its competitors? Incannex Healthcare's main competitors and comparable companies include Lifecore Biomedical (LFCR), LENZ Therapeutics (LENZ), NRx Pharmaceuticals (NRXP), Unicycive Therapeutics (UNCY), and Milestone Pharmaceuticals (MIST). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Incannex Healthcare compare to Lifecore Biomedical?

Lifecore Biomedical (NASDAQ:LFCR) and Incannex Healthcare (NASDAQ:IXHL) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.

83.4% of Lifecore Biomedical shares are held by institutional investors. Comparatively, 0.4% of Incannex Healthcare shares are held by institutional investors. 32.7% of Lifecore Biomedical shares are held by company insiders. Comparatively, 1.3% of Incannex Healthcare shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Incannex Healthcare has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -29.93%. Lifecore Biomedical's return on equity of 0.00% beat Incannex Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifecore Biomedical	-29.93%	N/A	-16.16%
Incannex Healthcare	N/A	-81.01%	-76.11%

In the previous week, Incannex Healthcare had 1 more articles in the media than Lifecore Biomedical. MarketBeat recorded 2 mentions for Incannex Healthcare and 1 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 1.83 beat Incannex Healthcare's score of 0.63 indicating that Lifecore Biomedical is being referred to more favorably in the media.

Company	Overall Sentiment
Lifecore Biomedical	Very Positive
Incannex Healthcare	Positive

Lifecore Biomedical has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market. Comparatively, Incannex Healthcare has a beta of 6.97, indicating that its stock price is 597% more volatile than the broader market.

Lifecore Biomedical currently has a consensus target price of $6.50, indicating a potential upside of 57.77%. Incannex Healthcare has a consensus target price of $18.00, indicating a potential upside of 452.15%. Given Incannex Healthcare's higher possible upside, analysts plainly believe Incannex Healthcare is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifecore Biomedical	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Lifecore Biomedical has higher revenue and earnings than Incannex Healthcare. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Incannex Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifecore Biomedical	$128.87M	1.21	-$40.50M	-$1.07	N/A
Incannex Healthcare	$90K	433.58	-$46.88M	-$1.55	N/A

Summary

Lifecore Biomedical beats Incannex Healthcare on 8 of the 14 factors compared between the two stocks.

How does Incannex Healthcare compare to LENZ Therapeutics?

Incannex Healthcare (NASDAQ:IXHL) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.

0.4% of Incannex Healthcare shares are held by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are held by institutional investors. 1.3% of Incannex Healthcare shares are held by company insiders. Comparatively, 8.3% of LENZ Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Incannex Healthcare has higher earnings, but lower revenue than LENZ Therapeutics. Incannex Healthcare is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incannex Healthcare	$90K	433.58	-$46.88M	-$1.55	N/A
LENZ Therapeutics	$19.09M	7.44	-$82.13M	-$4.09	N/A

Incannex Healthcare currently has a consensus target price of $18.00, suggesting a potential upside of 452.15%. LENZ Therapeutics has a consensus target price of $28.80, suggesting a potential upside of 537.17%. Given LENZ Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe LENZ Therapeutics is more favorable than Incannex Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
LENZ Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Incannex Healthcare has a beta of 6.97, suggesting that its share price is 597% more volatile than the broader market. Comparatively, LENZ Therapeutics has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market.

In the previous week, LENZ Therapeutics had 2 more articles in the media than Incannex Healthcare. MarketBeat recorded 4 mentions for LENZ Therapeutics and 2 mentions for Incannex Healthcare. LENZ Therapeutics' average media sentiment score of 1.04 beat Incannex Healthcare's score of 0.63 indicating that LENZ Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incannex Healthcare	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LENZ Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Incannex Healthcare has a net margin of 0.00% compared to LENZ Therapeutics' net margin of -586.74%. LENZ Therapeutics' return on equity of -53.39% beat Incannex Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incannex Healthcare	N/A	-81.01%	-76.11%
LENZ Therapeutics	-586.74%	-53.39%	-49.14%

Summary

LENZ Therapeutics beats Incannex Healthcare on 11 of the 16 factors compared between the two stocks.

How does Incannex Healthcare compare to NRx Pharmaceuticals?

Incannex Healthcare (NASDAQ:IXHL) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.

Incannex Healthcare currently has a consensus target price of $18.00, indicating a potential upside of 452.15%. NRx Pharmaceuticals has a consensus target price of $34.50, indicating a potential upside of 914.71%. Given NRx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe NRx Pharmaceuticals is more favorable than Incannex Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
NRx Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, NRx Pharmaceuticals had 6 more articles in the media than Incannex Healthcare. MarketBeat recorded 8 mentions for NRx Pharmaceuticals and 2 mentions for Incannex Healthcare. Incannex Healthcare's average media sentiment score of 0.63 beat NRx Pharmaceuticals' score of 0.61 indicating that Incannex Healthcare is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incannex Healthcare	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NRx Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

0.4% of Incannex Healthcare shares are owned by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are owned by institutional investors. 1.3% of Incannex Healthcare shares are owned by company insiders. Comparatively, 6.4% of NRx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Incannex Healthcare has a beta of 6.97, indicating that its share price is 597% more volatile than the broader market. Comparatively, NRx Pharmaceuticals has a beta of 2.19, indicating that its share price is 119% more volatile than the broader market.

NRx Pharmaceuticals has higher revenue and earnings than Incannex Healthcare. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Incannex Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incannex Healthcare	$90K	433.58	-$46.88M	-$1.55	N/A
NRx Pharmaceuticals	$1.23M	119.69	-$28.62M	-$0.55	N/A

Incannex Healthcare has a net margin of 0.00% compared to NRx Pharmaceuticals' net margin of -691.81%. NRx Pharmaceuticals' return on equity of 0.00% beat Incannex Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incannex Healthcare	N/A	-81.01%	-76.11%
NRx Pharmaceuticals	-691.81%	N/A	-63.92%

Summary

NRx Pharmaceuticals beats Incannex Healthcare on 11 of the 16 factors compared between the two stocks.

How does Incannex Healthcare compare to Unicycive Therapeutics?

Unicycive Therapeutics (NASDAQ:UNCY) and Incannex Healthcare (NASDAQ:IXHL) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends.

Unicycive Therapeutics has a beta of 1.79, meaning that its stock price is 79% more volatile than the broader market. Comparatively, Incannex Healthcare has a beta of 6.97, meaning that its stock price is 597% more volatile than the broader market.

Unicycive Therapeutics has higher revenue and earnings than Incannex Healthcare. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Incannex Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	$680K	216.66	-$26.56M	-$1.75	N/A
Incannex Healthcare	$90K	433.58	-$46.88M	-$1.55	N/A

Unicycive Therapeutics currently has a consensus target price of $18.75, suggesting a potential upside of 254.44%. Incannex Healthcare has a consensus target price of $18.00, suggesting a potential upside of 452.15%. Given Incannex Healthcare's higher probable upside, analysts clearly believe Incannex Healthcare is more favorable than Unicycive Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

40.4% of Unicycive Therapeutics shares are owned by institutional investors. Comparatively, 0.4% of Incannex Healthcare shares are owned by institutional investors. 6.0% of Unicycive Therapeutics shares are owned by company insiders. Comparatively, 1.3% of Incannex Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Incannex Healthcare's return on equity of -81.01% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	-91.50%	-61.47%
Incannex Healthcare	N/A	-81.01%	-76.11%

In the previous week, Unicycive Therapeutics had 26 more articles in the media than Incannex Healthcare. MarketBeat recorded 28 mentions for Unicycive Therapeutics and 2 mentions for Incannex Healthcare. Incannex Healthcare's average media sentiment score of 0.63 beat Unicycive Therapeutics' score of -0.01 indicating that Incannex Healthcare is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Unicycive Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	20 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral
Incannex Healthcare	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Unicycive Therapeutics beats Incannex Healthcare on 8 of the 15 factors compared between the two stocks.

How does Incannex Healthcare compare to Milestone Pharmaceuticals?

Milestone Pharmaceuticals (NASDAQ:MIST) and Incannex Healthcare (NASDAQ:IXHL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, media sentiment, profitability, risk, institutional ownership and analyst recommendations.

Milestone Pharmaceuticals presently has a consensus price target of $6.40, suggesting a potential upside of 552.99%. Incannex Healthcare has a consensus price target of $18.00, suggesting a potential upside of 452.15%. Given Milestone Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Milestone Pharmaceuticals is more favorable than Incannex Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Milestone Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Incannex Healthcare has lower revenue, but higher earnings than Milestone Pharmaceuticals. Incannex Healthcare is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Milestone Pharmaceuticals	$1.55M	78.72	-$63.06M	-$0.69	N/A
Incannex Healthcare	$90K	433.58	-$46.88M	-$1.55	N/A

Incannex Healthcare's return on equity of -81.01% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Milestone Pharmaceuticals	N/A	-288.33%	-58.27%
Incannex Healthcare	N/A	-81.01%	-76.11%

Milestone Pharmaceuticals has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market. Comparatively, Incannex Healthcare has a beta of 6.97, indicating that its share price is 597% more volatile than the broader market.

86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.4% of Incannex Healthcare shares are owned by institutional investors. 5.0% of Milestone Pharmaceuticals shares are owned by company insiders. Comparatively, 1.3% of Incannex Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Incannex Healthcare had 1 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 2 mentions for Incannex Healthcare and 1 mentions for Milestone Pharmaceuticals. Incannex Healthcare's average media sentiment score of 0.63 beat Milestone Pharmaceuticals' score of 0.62 indicating that Incannex Healthcare is being referred to more favorably in the news media.

Company	Overall Sentiment
Milestone Pharmaceuticals	Positive
Incannex Healthcare	Positive

Summary

Milestone Pharmaceuticals beats Incannex Healthcare on 10 of the 16 factors compared between the two stocks.

Get Incannex Healthcare News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IXHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IXHL vs. The Competition

Export

Metric	Incannex Healthcare	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$39.01M	$12.38B	$7.15B	$12.85B
Dividend Yield	N/A	2.64%	2.57%	11.17%
P/E Ratio	-2.10	799.75	274.94	25.36
Price / Sales	433.58	966.93	686.57	116.78
Price / Cash	N/A	88.17	76.65	51.52
Price / Book	1.57	10.39	10.33	6.20
Net Income	-$46.88M	$2.85B	$3.50B	$358.50M
7 Day Performance	0.62%	-3.61%	-3.32%	-2.35%
1 Month Performance	3.16%	0.72%	-0.53%	-3.23%
1 Year Performance	-80.15%	3.61%	23.51%	8.79%

Incannex Healthcare Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IXHL Incannex Healthcare	2.004 of 5 stars	$3.26 +0.3%	$18.00 +452.1%	-80.2%	$39.01M	$90K	N/A	3	Upcoming Earnings
LFCR Lifecore Biomedical	1.7649 of 5 stars	$4.46 -1.8%	$6.50 +45.7%	-45.2%	$171.85M	$128.87M	N/A	690	Analyst Upgrade
LENZ LENZ Therapeutics	3.2404 of 5 stars	$5.21 +2.0%	$28.80 +452.8%	-89.1%	$160.56M	$19.09M	N/A	110	Positive News Analyst Downgrade
NRXP NRx Pharmaceuticals	1.7536 of 5 stars	$3.48 -2.0%	$34.50 +891.4%	+21.4%	$153.70M	$1.23M	N/A	2	News Coverage
UNCY Unicycive Therapeutics	3.0258 of 5 stars	$5.20 -1.1%	$18.75 +260.6%	+36.7%	$146.66M	$680K	N/A	9	Trending News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IXHL) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Incannex Healthcare (IXHL) Competitors

IXHL vs. LFCR, LENZ, NRXP, UNCY, and MIST

How does Incannex Healthcare compare to Lifecore Biomedical?

Summary

How does Incannex Healthcare compare to LENZ Therapeutics?

Summary

How does Incannex Healthcare compare to NRx Pharmaceuticals?

Summary

How does Incannex Healthcare compare to Unicycive Therapeutics?

Summary

How does Incannex Healthcare compare to Milestone Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IXHL vs. The Competition

Incannex Healthcare Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Incannex Healthcare (IXHL) Competitors

IXHL vs. LFCR, LENZ, NRXP, UNCY, and MIST

How does Incannex Healthcare compare to Lifecore Biomedical?

Do institutionals and insiders have more ownership in LFCR or IXHL?

Is LFCR or IXHL more profitable?

Does the media prefer LFCR or IXHL?

Which has more volatility and risk, LFCR or IXHL?

Do analysts recommend LFCR or IXHL?

Which has preferable valuation and earnings, LFCR or IXHL?

Summary

How does Incannex Healthcare compare to LENZ Therapeutics?

Do insiders & institutionals hold more shares of IXHL or LENZ?

Which has stronger earnings & valuation, IXHL or LENZ?

Do analysts rate IXHL or LENZ?

Which has more volatility and risk, IXHL or LENZ?

Does the media prefer IXHL or LENZ?

Is IXHL or LENZ more profitable?

Summary

How does Incannex Healthcare compare to NRx Pharmaceuticals?

Do analysts recommend IXHL or NRXP?

Does the media prefer IXHL or NRXP?

Do institutionals and insiders believe in IXHL or NRXP?

Which has more volatility and risk, IXHL or NRXP?

Which has stronger earnings & valuation, IXHL or NRXP?

Is IXHL or NRXP more profitable?

Summary

How does Incannex Healthcare compare to Unicycive Therapeutics?

Which has more risk & volatility, UNCY or IXHL?

Which has better earnings & valuation, UNCY or IXHL?

Do analysts rate UNCY or IXHL?

Do institutionals and insiders hold more shares of UNCY or IXHL?

Is UNCY or IXHL more profitable?

Does the media prefer UNCY or IXHL?

Summary

How does Incannex Healthcare compare to Milestone Pharmaceuticals?

Do analysts prefer MIST or IXHL?

Which has preferable valuation and earnings, MIST or IXHL?

Is MIST or IXHL more profitable?

Which has more volatility & risk, MIST or IXHL?

Do insiders & institutionals hold more shares of MIST or IXHL?

Does the media prefer MIST or IXHL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IXHL vs. The Competition

Incannex Healthcare Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools